The activity of adenosine monophosphate-activated protein kinase in lymphocytes under the action of hypoglycemic drugs
DOI:
https://doi.org/10.15407/dopovidi2017.06.096Keywords:
AMPK, dapagliflozin, diabetes, metforminAbstract
We have studied the activity of adenosine monophosphate-activated protein kinase (AMPK), which controls the energy balance in a cell, after the treatment of patients with diabetes with hypoglycemic agents. It is shown for the first time that metformin increases the AMPK activity in lymphocytes. Dapagliflozin, an inhibitor of sodium-dependent glucose transporter, also increases the protein kinase activity in blood cells and exerts an additive effect to metformin. The mechanisms of impact of the antidiabetic drugs on the level of AMPK activity are discussed.
Downloads
References
Saha, A.K., Xu, X.J., Balon, T.W. et al. (2011). Insulin resistance due to nutrient excess. Is it a consequence of AMPK downregulation? Cell Cycle, 10, No. 20, pp. 3447-3451. https://doi.org/10.4161/cc.10.20.17886
Filippatos, T.D., Liberopoulos, E.N. & Elisaf, M.S. (2015). Dapagliflozin in patients with type 2 diabetes mellitus. Ther. Adv. Endocrinol. Metab., 6, No. 1, pp. 29-41. https://doi.org/10.1177/2042018814558243
Ruderman, N.B., Carling, D., Prentki, M. & Cacicedo, J.M. (2013). AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest., 123, No. 7, pp. 2764-2772. https://doi.org/10.1172/JCI67227
Xiao, B., Sanders, M.J., Underwood, E. et al. (2011). Structure of mammalian AMPK and its regulation by ADP. Nature, 472, No. 7342, pp. 230-233. https://doi.org/10.1038/nature09932
Racioppi, L. & Means, A.R. (2012). Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and patho physiology. J. Biol. Chem., 287, No. 38, pp. 31658-31665. https://doi.org/10.1074/jbc.R112.356485
Jeong, K.J., Kim, G.W. & Chung, S.H. (2014). AMP-activated protein kinase: An emerging target for ginseng. J. Ginseng Res., 38, pp. 83-88. https://doi.org/10.1016/j.jgr.2013.11.014
An, H. & He, L. (2016). Current understanding of metformin effect on the control of hyperglycemia in diabetes. J. Endocrinol., 228, No. 3, pp. R97-R106. https://doi.org/10.1530/JOE-15-0447
Meng, S., Cao, J., He, Q. et al. (2015). Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex. J. Biol. Chem., 290, pp. 3793-3802. https://doi.org/10.1074/jbc.M114.604421
Chang, Y.K., Choi, H., Jeong, J.Y. et al. (2016). Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemiareperfusion injury. PLoS One, 11, No. 7, e0158810. https://doi.org/10.1371/journal.pone.0158810
Zinman, B., Wanner, C., Lachin, J.M. et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl. J. Med., 373, No. 22, pp. 2117-2128. https://doi.org/10.1056/NEJMoa1504720
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Reports of the National Academy of Sciences of Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
